- Home
- TRUE vs TLSI Comparison
TRUE vs TLSI Comparison
Compare TRUE & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRUE
- TLSI
- Stock Information
- Founded
- TRUE 2005
- TLSI 2010
- Country
- TRUE United States
- TLSI United States
- Employees
- TRUE N/A
- TLSI 110
- Industry
- TRUE Computer Software: Programming Data Processing
- TLSI Medical Specialities
- Sector
- TRUE Technology
- TLSI Health Care
- Exchange
- TRUE Nasdaq
- TLSI Nasdaq
- Market Cap
- TRUE 171.0M
- TLSI 150.0M
- IPO Year
- TRUE 2014
- TLSI N/A
- Fundamental
- Price
- TRUE $2.05
- TLSI $3.95
- Analyst Decision
- TRUE Buy
- TLSI Strong Buy
- Analyst Count
- TRUE 5
- TLSI 5
- Target Price
- TRUE $3.19
- TLSI $10.90
- AVG Volume (30 Days)
- TRUE 459.4K
- TLSI 58.3K
- Earning Date
- TRUE 08-06-2025
- TLSI 08-12-2025
- Dividend Yield
- TRUE N/A
- TLSI N/A
- EPS Growth
- TRUE N/A
- TLSI N/A
- EPS
- TRUE N/A
- TLSI N/A
- Revenue
- TRUE $184,559,000.00
- TLSI $32,141,000.00
- Revenue This Year
- TRUE $7.54
- TLSI $55.39
- Revenue Next Year
- TRUE $11.02
- TLSI $54.89
- P/E Ratio
- TRUE N/A
- TLSI N/A
- Revenue Growth
- TRUE 11.66
- TLSI 46.20
- 52 Week Low
- TRUE $1.05
- TLSI $3.46
- 52 Week High
- TRUE $4.62
- TLSI $6.04
- Technical
- Relative Strength Index (RSI)
- TRUE 58.18
- TLSI 34.89
- Support Level
- TRUE $1.53
- TLSI $3.46
- Resistance Level
- TRUE $2.29
- TLSI $4.30
- Average True Range (ATR)
- TRUE 0.18
- TLSI 0.30
- MACD
- TRUE 0.00
- TLSI -0.05
- Stochastic Oscillator
- TRUE 68.87
- TLSI 35.77
About TRUE TrueCar Inc.
TrueCar Inc is a data-driven online platform operating on common technology infrastructure, powered by proprietary data and analytics. It also customizes and operates its platform for affinity group marketing partners, including financial institutions like PenFed and American Express; membership-based organizations like Consumer Reports, AARP, Sam's Club, and AAA; and employee buying programs for large enterprises such as IBM and Walmart. The Company has one operating segment, with three distinct service offerings: Dealer products and services, OEM incentives, and other.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.